MOTS-c vs Tirzepatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.

Full details →

Tirzepatide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.

Full details →

Side-by-Side Comparison

AspectMOTS-cTirzepatide
MechanismActivates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis.Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy.
Typical DosageResearch protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established.Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks.
AdministrationSubcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation.Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects.
Side EffectsLimited human data. Animal studies show good tolerability. May affect energy levels and exercise performance.Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use.
Best For

What They Have in Common

Both MOTS-c and Tirzepatide are commonly used for:

Key Differences

Ready to Learn More?